MMRF PRESS RELEASES
Multiple Myeloma Research Foundation (MMRF) Announces Janssen Research & Development, LLC Joins Innovative Pre-competitive Consortium to Advance Personalized Medicine Approaches for Multiple Myeloma
Unique Collaboration Supports Landmark Multiple Myeloma Study
Norwalk, CT — June 20, 2013
The Multiple Myeloma Research Foundation (MMRF) today announced that Janssen Research & Development, LLC (Janssen R&D) has joined the MMRF pre-competitive consortium (PCC) to discover and accelerate new approaches to treating multiple myeloma through the organization’s Personalized Medicine Initiative (PMI).
The cornerstone of the PMI is the landmark MMRF CoMMpass℠ Study (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile) which is collecting cutting-edge, comprehensive clinical information and molecular profiles of 1,000 newly diagnosed patients over a minimum of five years. Data collected from CoMMpass will provide researchers with insights needed to more completely characterize the genetic subtypes of multiple myeloma based on responsiveness to specific treatment regimens, ultimately enabling individualized treatment approaches for multiple myeloma.
The study, which opened to enrollment in July 2011, has more than 50 active sites that have screened more than 300 patients to date. Later this year, CoMMpass study data will be made available to academic and industry researchers worldwide via a publicly shared data system to enable open access analysis, and worldwide collaboration to stimulate hypothesis generation. Members of the PCC provide scientific and financial support for the PMI. This innovative, collaborative and diverse partnership structure provides researchers access to the findings from CoMMpass, to accelerate drug discovery and development in multiple myeloma and potentially other cancers sharing the same targets.
“Our partnership with the oncology industry’s leaders will help to drive scientific and clinical innovation through new models of collaboration,” stated Walter M. Capone, Chief Operating Officer of the MMRF. “We are deeply gratified to have Janssen R&D join this breakthrough initiative, and sincerely appreciate all the members of the PCC for their vision, commitment, and support of our mission to accelerate the translation of research findings into therapeutic advancements for patients.”
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 41 percent, one of the lowest of all cancers. In 2013, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $225 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 10 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.
Anne Quinn Young